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Abstract
Background: High dietary intake of selenium or isoflavones reduces risk factors for prostate cancer. We
tested whether combined supplementation of these two dietary components would reduce prostate
cancer risk factors in rats more than supplementation of each component individually.
Methods: Male Noble rat pups were exposed from conception to diets containing an adequate (0.33–
0.45 mg/kg diet) or high (3.33–3.45 mg/kg) concentration of selenium as Se-methylselenocysteine and a
low (10 mg/kg) or high (600 mg/kg) level of isoflavones in a 2 × 2 factorial design. Pups consumed their
respective diets until sacrifice at 35, 100, or 200 days. Male Noble rat breeders, whose exposure to the
diets began after puberty, were sacrificed at 336 days. Rats were weighed biweekly. Blood was collected
at the time of sacrifice and body fat and prostates were dissected and weighed. Serum levels of leptin, IGF-
1, and testosterone were determined using ELISA kits. Serum levels of isoflavones were assayed by GC/
MS. Liver activity of selenium-dependent glutathione peroxidase 1 was measured as an indicator of
selenium status.
Results: Serum isoflavone concentrations were nearly 100-fold higher at 35 days of age (1187.1 vs. 14.4
ng/mL, mean ± SD) in pups fed the high vs. low isoflavone diets, and remained so at 100 and 200 days, and
in breeders. There were no dietary differences in liver glutathione peroxidase activity in pups or breeders.
High isoflavone intake significantly (p = 0.001–0.047) reduced body weight in rat pups from 35 days
onward, but not in breeders. Body fat and leptin were likewise significantly reduced by high isoflavones in
pups while effects in breeders were less pronounced but still significant. High intake of Se and isoflavones
each decreased serum IGF-1 in pups at 100 and 200 days, but not in breeders. No consistent dietary effects
were observed on serum testosterone or relative weights of prostates. In pups, the combination of high
isoflavones and high selenium produced the lowest weight gain, the lowest serum leptin, and the lowest
serum IGF-1 concentrations of all four diets.
Conclusion:  Combined intake of high selenium and high isoflavones may achieve greater
chemopreventive effects than either compound individually. The timing of supplementation may determine
the significance of its effects.
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Background
Prostate cancer is the most frequently diagnosed cancer
and the second leading cause of cancer deaths in Ameri-
can men. The American Cancer Society projects that there
will be 186,320 new cases of prostate cancer in the U.S. in
2008, and 28,660 deaths from this disease [1]. The high
occurrence and long latency period of prostate cancer
make it a good candidate for intervention and chemopre-
vention by diet and other means.
Many host factors, including the hormonal profile to
which tumors are exposed, contribute to their growth and
spread. Obesity and excess body fat increase risk of several
cancers, including that of aggressive prostate cancer [2].
High plasma concentrations of insulin and insulin-like
growth factors (e.g. IGF-1) are likewise associated with
increased risk [3,4]. Serum leptin concentrations show a
direct association with prostate cancer risk [5-7], and tes-
tosterone is a well-known promoter of the growth of both
normal prostate tissue and prostate tumors [8,9]. Several
of these factors are responsive to dietary manipulation.
Selenium (Se) and soy products containing isoflavones
are among the most promising dietary constituents whose
intake may reduce risk for prostate cancer [10,11] and
among the most popular supplements taken by men in a
recent prostate cancer trial [12]. In their review of diet in
the development and progression of prostate cancer,
Chan et al. [13] found the evidence more convincing for a
protective effect of the essential trace element Se than for
any other dietary component. Several lines of evidence
confirm the chemopreventive efficacy of high dietary Se
intake or status against prostate cancer [14-18]. The World
Cancer Research Fund and American Institute for Cancer
Research [19], in their recently released summary, con-
cluded that "The evidence from cohort and case-control
studies is consistent, with a dose-response relationship.
There is evidence for plausible mechanisms. Foods con-
taining selenium probably protect against prostate can-
cer."
Molecular targets for Se have been identified [15,20,21]
and mechanisms for its protective effects have been pro-
posed [22-27]. These mechanisms include alteration of
various aspects of steroid hormone metabolism [27,28].
Prostate cancers rates are particularly low in Asian coun-
tries where the typical diet contains high levels of soy
products [29]. In contrast, the highest rates of prostate
cancer are seen in countries where the so-called "Western
diet" is the norm and intake of soy products is very low
[19,30-33]. Many investigators have attributed the inverse
correlation between soy intake and prostate cancer to the
estrogenic isoflavones found in soy [34-36]. High intake
of soy products has been correlated in epidemiologic
[37,38] and case control studies [39] with reduced risk for
prostate cancer, although not all studies are in agreement
[40,41]. Mechanisms for the chemopreventive effects of
soy have been reviewed [42,43]. Effects of phytoestrogen
consumption may depend in part on genotype [44]. Much
of the mechanistic work related to soy consumption has
focused on individual isoflavones supplemented in cell
culture medium or provided to animals by injection or
diet. Among other effects, dietary isoflavones have been
shown to modify body weight [45,46], deposition of body
fat [46,47], leptin [46,47] and insulin [47,48] levels, and
various aspects of steroid hormone metabolism
[47,49,50].
In this study we investigated the effects of combined die-
tary supplementation of Se and isoflavones to determine
if risk factors for prostate cancer might be reduced more
by their combined use than by supplementation of either
dietary component individually. The molecular mecha-
nisms by which Se and soy isoflavones act individually are
being critically examined by many investigators, but the
potential chemopreventive efficacy of combining supple-
mentation of these two dietary components remains to be
explored.
Methods
All procedures involving animals were approved by the
BYU Institutional Animal Care and Use Committee. Male
and female Noble rats, aged 35–42 days were purchased
from Charles River Laboratories (Wilmington, MA).
Females were housed individually in shoebox cages and
males were housed individually in hanging wire cages. For
breeding, females were placed with males in the hanging
wire cages, which facilitated identification of the vaginal
plug after mating. Following the appearance of the plug,
females were returned to their shoebox cages. All cages
were kept in a temperature- and light-controlled room (12
h, 0600–1800, light:12 h, 1800–0600, dark). Animals
were given free access to food (as described below) and
tap water.
Four males and eight females were assigned to each of the
four experimental diets. After consuming their respective
diets for at least 30 days males and females within each
dietary group were bred to produce pups whose exposure
to the diets began at conception. Dams continued con-
suming their respective diets through pregnancy and lac-
tation. Male pups were weaned at 21 days of age to the
same diets consumed by their dams, and used as experi-
mental subjects. Male breeders continued to consume
their respective diets until they were sacrificed at approxi-
mately 336 days of age. Thus, continued feeding of breed-
ers made possible comparisons between animals whose
exposure to the diets began at conception and those
whose exposure began after sexual maturity.Nutrition & Metabolism 2008, 5:31 http://www.nutritionandmetabolism.com/content/5/1/31
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Rats were fed one of two basal stock diets, with or without
a supplement of Se, in a 2 × 2 factorial design. Stock diets
were 1) a phytoestrogen-reduced formulation (Zeigler
Bros., Inc., Gardners, PA; Phytoestrogen Reduced Diet I);
or 2) a standard soy-based laboratory chow (8604, Harlan
Teklad, Madison, WI). Previous analysis showed these for-
mulations to contain approximately 10 (Low) and 600
mg (High) isoflavones/kg diet, respectively [51]. Product
data sheets reported that the basal diets contained 0.33–
0.45 mg Se/kg diet (Adequate Se). Half of the diets were
supplemented with 3.0 mg/kg Se as Se-methylseleno-
cysteine (a generous gift from Kelatron Corp., Ogden, UT;
High Se). A detailed analysis of the two basal stock diets is
shown in Additional file 1.
Rats were weighed biweekly. All rats were weighed imme-
diately prior to sacrifice. Eight pups in each dietary group
were killed at 35, 100, or 200 days of age by decapitation.
Breeders were sacrificed at approximately 336 days of age.
Blood was collected, allowed to clot, and centrifuged at
1000 × g for 10 minutes to separate serum from clotting
factors and cells. White adipose tissue was dissected from
the abdomino-pelvic cavity of 200 day old rats and breed-
ers, and weighed. For pups and breeders, testis and ventral
prostate lobes were dissected and weighed. Livers were
also dissected and flash frozen in liquid nitrogen for sub-
sequent analysis of cellular Se-dependent glutathione per-
oxidase 1 (EC 1.11.1.9; GPX1) activity.
Analysis of serum isoflavone content was performed as
described previously [52]. Briefly, phytoestrogen concen-
trations were analyzed for each dietary treatment group
via gas chromatography/mass spectrometry (GC/MS).
This was performed by liquid-solid extraction and liquid
gel chromatographic techniques to isolate the phytoestro-
gen fractions using standards (internal controls) to vali-
date the assay. As a measure of Se status, activity of GPX1
was assayed in cytosolic fractions from livers of all ani-
mals at each time point in each of the four dietary groups,
and in breeders, as previously described [53].
Serum hormone levels were assayed using commercially
available ELISA kits according to the manufacturers' direc-
tions. IGF-1 was measured using R&D Systems Mouse
IGF-1 Immunoassay Quantikine kit (#MG100, Minneap-
olis, MN). Intra-assay precision of this kit ranges from
3.3–5.6% (CV) and inter-assay precision ranges from 4.3–
9.0% (CV). Testosterone was assayed using an ELISA kit
from Fitzgerald Industries International Inc. (#RDI-
RE52151, Concord, MA). Intra-assay variation for this kit
ranges from 3.28–4.16% (CV) while inter-assay variation
is between 4.73–9.94% (CV). The mouse/rat leptin ELISA
kit used was from BioVendor (#RD291001200, Candler,
NC). For this kit, reported intra-assay variability (CV) is
2.2%, while inter-assay variability (CV) is 3.4%. Micro-
plates were read on a FLUOstar Optima microplate reader
(BMG Labtech, Durham, NC).
Statistical analysis was performed by analysis of variance
(ANOVA) using the General Linear Model in SAS (SAS
Institute Inc., Cary, NC) to determine main effects of Se
and isoflavones, and their interactions. This was followed
by Fisher's and Tukey's pairwise comparisons to deter-
mine significance of differences between dietary groups.
Differences for which p values were < 0.05 were judged
statistically significant.
Results
Nutritional status indicators
Serum isoflavone levels (genistein + daidzein + equol)
were significantly higher in rats fed the high isoflavone
diets, even at the earliest time point measured. At 35 days
serum concentrations averaged 1235 ± 117 (mean ± SD)
and 1140 ± 275 ng/mL in rat pups consuming high isofla-
vone diets, with and without a 3.0 mg/kg Se supplement,
respectively. In contrast, serum concentrations in pups fed
the low isoflavone diets, with and without the Se supple-
ment, averaged 11.9 ± 4.1 and 16.8 ± 2.5 ng/mL, respec-
tively. Supplemental Se had no effect on serum isoflavone
levels. These differences persisted at 100 days and at 200
days in pups, and comparable differences were seen in
breeders (1419 ± 135 vs. 17.3 ± 3.2 ng/mL, in rats fed 600
vs. 10 mg isoflavones/kg diet, respectively). The serum
isoflavone concentrations in rats fed 600 mg/kg were sim-
ilar to those seen in adults in Asian countries while the
serum levels in rats fed only 10 mg/kg were comparable to
those in persons consuming diets typical of Western coun-
tries [31,54].
There were no statistically significant differences due to
diet at any time point, in pups or in breeders, in the activ-
ity of hepatic GPX1. This was expected since all diets pro-
vided a Se concentration higher than needed to maximize
GPX1 activity in rat liver [55]. Mean activities at different
time points in the four dietary groups ranged from 461.6–
868.7 mU/mg protein, which were comparable to previ-
ously published values for GPX1 activity in Se-adequate
rat liver [53,56].
Growth and body composition
Diet had a significant effect on weight gain of rat pups
(Figure 1A). From 35 days until termination of the feeding
period the main effect of isoflavones was significant in
reducing body weight (p = 0.047 and p = 0.001 at 35 days
and 200 days, respectively). Only at the 35 day time point
did the main effect of Se approach statistical significance
(p = 0.05). In contrast to the effects in pups exposed to
their respective treatments from conception, diet had no
statistically significant effect on body weight of breedersNutrition & Metabolism 2008, 5:31 http://www.nutritionandmetabolism.com/content/5/1/31
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whose exposure to the diets began after sexual maturity
(Figure 1B).
Comparable to its effects on body weight, high isoflavone
intake was associated with significantly lower body fat in
200 day old rat pups (p < 0.001; Figure 2A). Dietary Se
intake had no statistically significant effect on body fat (p
= 0.779) nor was the interaction between Se and isofla-
vones significant. In breeders the main effect of phytoes-
trogen consumption was significant (p = 0.038) while
effects of Se and the interaction were not (Figure 2B).
There were no consistent, significant effects of diet on rel-
ative weights (g/100 g body weight) of ventral prostate
lobes or of testis in pups at different time points or in
breeders.
Serum hormone concentrations
Serum leptin in pups exposed to diets from conception
followed the same pattern as body weight and body fat
(Figure 3A). Interestingly, the effects of Se and isoflavones
varied over time. At 35 days the main effect of Se on serum
leptin levels was significant (p < 0.001) while the effect of
isoflavones was not (p = 0.637). At 100 days the main
Weight gain of pups and breeders Figure 1
Weight gain of pups and breeders. A. Body weights of pups. Symbols and error bars represent means ± SEM for each die-
tary group at each time point. N = 23–24 rats/group up to 35 days, N = 15–16 rats/group from 35–100 days, and from 100–
200 days N = 8 rats/group. By ANOVA, diet was a significant determinant (p < 0.005) of body weight as early as 35 days, which 
significance continued until the end of the study. At 35 days and 200 days means not sharing a common superscript are signifi-
cantly (p < 0.05) different by Fisher's pairwise comparisons. The main effect of isoflavones was statistically significant at each 
time point (p = 0.047 and p = 0.001 at 35 days and 200 days, respectively) while the main effect of Se was not. B. Body weights 
of breeders. N = 3–4 for each dietary group at each time point. Symbols and error bars represent means ± SEM for each die-
tary group at each time point. There were no statistically significant effects of diet on body weight at any time point. Abbrevia-
tions: Adequate (0.33–0.45 mg/kg diet) Se, Adq. Se; High (3.33–3.45 mg/kg) Se, High Se; Low (10 mg/kg) isoflavones, Low IF; 
High (600 mg/kg) isoflavones, High IF.
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effect of each dietary component was significant (isofla-
vones, p = 0.033; Se, p = 0.001), with high intake of each
being associated with lower leptin levels. By the time rats
were 200 days old, the effect of isoflavones was pro-
nounced (p < 0.001) but the effect of Se was no longer sig-
nificant (p = 0.068). As seen in Figure 3B, the pattern of
dietary effects in breeders was similar to that in 200 day
old pups. High isoflavone intake significantly (p = 0.004)
reduced serum leptin levels, while high Se intake had no
effect (p = 0.807).
Concentrations of IGF-1 were affected by diet in pups at
all time points (Figure 4A) but not in breeders (Figure 4B).
At 35 days, effects of Se (p < 0.0001), isoflavones (p =
0.019), and the interaction (p = 0.004) were all statisti-
cally significant. At 100 days, the main effects of Se (p =
0.022) and isoflavones (p < 0.0001) were each significant
but the interaction was not. At 200 days, Se (p = 0.003)
and isoflavones (p = 0.046) each had significant main
effects, and the interaction was also significant (p =
0.034). In breeders, neither dietary component signifi-
cantly affected serum IGF-1 levels.
There were no consistent, significant effects of diet on
serum testosterone levels in pups at different time points
or in breeders.
Discussion
The findings in this study of decreased body weight,
decreased adiposity, and decreased leptin due to high iso-
Body Fat of Pups and Breeders Figure 2
Body fat of pups and breeders. A. Body fat, as a percentage of body weight, in pups sacrificed at 200 days of age. Bars and 
error bars represent means + SEM for each dietary group, N = 8 rats/group. The main effect of isoflavones was highly signifi-
cant (p < 0.001) while the effect of Se and of the interaction were not. Means not sharing a common superscript are signifi-
cantly (p < 0.05) different by Fisher's pairwise comparisons. B. Body fat, as a percentage of body weight, in breeders sacrificed 
at approximately 336 days of age. Bars and error bars represent means + SEM for each dietary group, N = 3–4 rats/group. The 
main effect of isoflavones was significant (p = 0.038) while the effects of Se and the interaction were not. Means not sharing a 
common superscript are significantly (p < 0.05) different by Fisher's pairwise comparisons.
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flavone consumption are consistent with most previous
reports [46,47,57,58] but at variance with others [59,60].
In the Noble rats used in this study neither high Se nor
high isoflavone intake had a consistent, significant effect
on serum testosterone levels or prostate weights. In earlier
investigations in our laboratories and others, high dietary
isoflavone intake either decreased [61,62] or had no effect
[63,64] on serum testosterone levels, and reduced
[61,64,65] or did not affect [63] prostate weights. These
differences in phytoestrogen effects in previous studies
may be due, in part, to the different rat strains used in
those studies. A recent report [66] showed that Sprague-
Dawley rats were less sensitive to phytoestrogens than
Fisher 344 rats or CD-1 mice in evaluations of estrogenic
activity. To compare results from the present study with
those found in previous experiments employing Noble
rats, a computer-assisted literature search was conducted.
That search found only one published paper presenting
results from a study examining soy effects in Noble rats,
which showed anti-inflammatory effects in the prostate
but no effect on the weights of testis or accessory sex
glands [67].
It is of interest to note that pronounced dietary effects seen
in rat pups, exposed to the various diets from conception,
were in some cases minimal or totally absent in breeders,
whose exposure to the diets began after sexual maturity.
While this result may be due in part to the relatively small
Serum leptin in pups and breeders Figure 3
Serum leptin in pups and breeders. A. Mean serum leptin concentration in pups at 35, 100, and 200 days of age. Symbols 
and error bars represent means ± SEM for each dietary group at each time point. At 35 days N = 23–24 rats/group, at 100 days 
N = 15–16 rats/group, and at 200 days N = 8 rats/group. At each time point, means not sharing a common superscript are sig-
nificantly (p < 0.05) different by Fisher's pairwise comparisons. At 35 days only Se had a significant effect (p < 0.001) on serum 
leptin concentrations. At 100 days both Se (p = 0.001) and isoflavones (p = 0.033) had significant main effects. At 200 days only 
isoflavone intake had a significant main effect (p < 0.001). B. Mean serum leptin concentration in male breeders at 336 days. 
Only the main effect of isoflavones was statistically significant (p = 0.004). Means not sharing a common superscript are signifi-
cantly (p < 0.05) different by Fisher's pairwise comparisons.
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number (3–4) of breeders in each dietary group, similar
findings suggesting prenatal imprinting or programming
due to diet have been previously reported. Mardon et al.
[59] showed that prenatal or perinatal exposure of Wistar
rats to phytoestrogens led to a high bone mineral density
later in life, compared to animals receiving postnatal
exposure. Klein et al. [68] demonstrated long-lasting
effects of early exposure to genistein on the immune and
endocrine systems of rats. Prepubertal exposure to genis-
tein was shown in other work to increase mammary gland
differentiation and suppress DMBA-induced cancer [69].
Besides its effects on serum leptin levels, which decreased
with the age of the rat, high dietary Se intake had a statis-
tically significant main effect only on serum IGF-1 levels.
The decrease in IGF-1 serum level due to high Se was
highly significant in rat pups at 35, 100, and 200 days, but
non-significant in breeders. This observation suggests
that, like isoflavones, Se may also be involved in prenatal
programming or imprinting of later biological response.
Effects of Se on IGF-1 have been examined in compara-
tively few studies. Chandrasekher and Sailaja [70] found
that Se significantly inhibited the ability of IGF-1 to stim-
ulate PI3K activity in cultured lens epithelial cells. More
relevant to the present work, Meltzer and Haug [71] fed
women daily supplements of 100–300 μg Se as Se-rich
bread for 6 weeks, or 400 μg selenomethionine for 15
Serum IGF-1 in pups and breeders Figure 4
Serum IGF-1 in pups and breeders. A. Serum IGF-1 concentrations in pups sacrificed at 35, 100, and 200 days of age. Bars 
and error bars represent means + SEM for each dietary group, N = 7–8 rats/group. For each time point, means not sharing a 
common superscript are significantly (p < 0.05) different using Fisher's or Tukey's pairwise comparisons. At each time point the 
main effects of Se (p < 0.0001, p = 0.022, and p = 0.003 at 35 days, 100 days, and 200 days, respectively) and of isoflavones (p 
= 0.019, p = 0.022, and p = 0.046 at 35 days, 100 days, and 200 days, respectively) were statistically significant. Interactions 
were statistically significant at 35 days (p = 0.004) and 200 days (p = 0.034). B. Serum IGF-1 concentrations in male breeders 
sacrificed at approximately 336 days of age. Neither isoflavones nor Se was significantly associated with serum IGF-1 levels in 
breeders.
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weeks. Although serum Se levels were significantly
increased, no significant changes in IGF-1 were observed.
These results were comparable to those seen with breeder
rats in this study. Previous work in rats showed that high
levels of Se that decreased IGF-1 concentrations also were
growth inhibitory [71]. In this work, the main effect of Se
on IGF-1 was statistically significant, but no growth effects
of Se were observed. This provides clear evidence that,
although the supplemented diets provided high levels of
Se (3.33–3.45 mg/kg diet), this level was non-toxic to
growing Noble rats.
Given the complexity of cancer, with dysfunctional
changes at multiple stages and in multiple metabolic
pathways, it is perhaps not surprising that the results of
clinical trials of single agents have been largely disap-
pointing. This has prompted some investigators to pro-
pose a redefinition of "dietary chemoprevention" to focus
on combinations and "cocktails" of dietary agents to
reduce risk for cancer [72]. Our use in this study of a com-
bination of Se supplements with high isoflavone diets is
consistent with this recommendation. It is important to
note in this study that in pups exposed to test diets from
conception, the combination of high Se with high isofla-
vones resulted in the lowest weight gain (Figure 1A), the
lowest serum leptin (Figure 3A), and the lowest serum
IGF-1 concentrations (Figure 4A) of all four dietary treat-
ments. This finding has obvious implications for men in
whom prostate cancer risk is increased by higher fat mass
[2], higher serum leptin [5-7,73], and/or higher IGF-1 lev-
els [3,4,74,75].
Conclusion
In summary, high isoflavone intake decreased weight
gain, body fat mass, and serum leptin in rat pups exposed
to experimental diets from conception. Exposure of breed-
ers to the same diets beginning after sexual maturation
produced minimal or no effects. This observation pro-
vides support for the possibility of in utero imprinting by
high isoflavone intake and may call into question the
merit of beginning isoflavone supplementation in mature
men diagnosed with prostate cancer. High intake of die-
tary Se was associated in this study with decreased IGF-1
levels in pups prenatally exposed, but not in breeders, sug-
gesting the possibility of prenatal programming by Se, as
well. Combining high isoflavones with high Se produced
the greatest effects on the parameters measured. This find-
ing provides support for the combination approach to
cancer chemoprevention by dietary constituents being
advocated by an increasing number of investigators.
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